Press Releases and Announcements

April 9, 2016 Altor BioScience Corporation Announces the Appointment of Dr. Patrick Soon-Shiong as Chairman of its Board of Directors
October 6, 2015 Altor Bioscience Announces NCI Phase II SBIR Grant Award and Publication Supporting Ongoing Clinical Trial of IL-15 Super Agonist ALT-803 in Combination with Anti-CD20 Antibody Therapy for Relapsed / Refractory Non-Hodgkin Lymphoma
May 28, 2015 Altor BioScience Announces Upcoming Data Presentation on Efficacy and Safety of ALT-801 for Advanced Bladder Cancer at 2015 ASCO Annual Meeting
January 6, 2015 Altor BioScience Corporation Announces the Appointment of Kevin Taylor as Chief Business Officer
November 4, 2014 Altor BioScience Initiates Clinical Development of its Novel IL-15 Super Agonist ALT-803 for Relapsed / Refractory Multiple Myeloma Supported by a Newly Awarded Phase II SBIR Grant from NCI
September 9, 2014 Altor BioScience and Shenzhen Beike Biotechnology Announce License Agreement for Immunotherapeutic ALT-803 in China
August 19, 2014 Altor BioScience Awarded SBIR Phase II Grant by NCI for Clinical Development of its Novel IL-15 Super Agonist for Non-muscle Invasive Bladder Cancer
May 21, 2014 Position Announcement - Research Associate/Senior Research Associate
August 15, 2013 Altor Bioscience Launches its Proprietary IL-15 Superagonist ALT-803 into Clinical Trials against Cancer
September 27, 2012 Altor BioScience Awarded Two SBIR Phase I Grants by NCI for Research on its Novel IL-15 Super Agonists for Hematologic Cancers
April 30, 2012 Altor BioScience and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma
August 17, 2011 Altor BioScience Awarded SBIR Phase I Grant by NCI for Research on its Novel IL-15 Super Agonist for Bladder Cancer
June 28, 2011 Florida Biologix Announces Manufacturing Agreement with Altor BioScience
May 23, 2011 Altor BioScience Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI to Complete a Second Phase 2 ALI/ARDS Clinical Trial for its Antibody-based Tissue Factor Antagonist, ALT-836
February 16, 2011 Altor BioScience Awarded SBIR Phase I Grant by NIAID for HIV Research
January 24, 2011 Cancer play Altor stays majority-owned by individuals to pursue SBIRs Less VC, more SBIR
November 3, 2010 S. Fla. biotechs get federal financial boost
September 25, 2009 Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801
October 22, 2008 Altor BioScience is Awarded Grant from the Bill & Melinda Gates Foundation
September 10, 2008 Altor BioScience Licenses T-cell Receptors Targeting HIV and Hepatitis C from Massachusetts General Hospital
February 12, 2008 Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
December 20, 2007 Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801
July 25, 2006 Altor BioScience Awarded Phase II SBIR Grant for Anti-Cancer Antibody Manufacture in Transgenic Plants
March 13, 2006 Altor BioScience Introduces STAR(TM) Multimer Reagents to Measure Disease-Specific Antigen Presentation
July 21, 2005 Altor BioScience Awarded SBIR Grant for Manufacturing Therapeutic Antibodies in Transgenic Plants
January 19, 2005 Altor BioScience Establishes Collaboration with Leading MGH Investigator to Develop TCR-based Agents to Detect and Treat HIV and HCV Infection
September 20, 2004 Altor Bioscience Receives Phase II SBIR Grant for Next-Generation Cancer Therapeutics
March 29, 2004 Altor BioScience Reports Advancements in its Soluble T-cell Receptor-Based Technology Programs
November 11, 2003 Altor Bioscience Reports Pre-Clinical Results Supporting Utility of Soluble T-Cell Receptor Fusions for Cancer Immunotherapy
September 26, 2003 Altor Bioscience Awarded NIH Grant to Expand Screening Program to Identify Orally Available Drugs to Treat Multiple Sclerosis
June 1, 2003 Altor Bioscience Receives SBIR Grant from NIAID for Development of Anti-Viral TCR Therapeutics
March 18, 2003 Altor Bioscience Issued New U.S. Patent for Innovative T-cell Receptor Technology

Other Publicity

  • Altor featured on NCI's website as a success story (Link)
  • Altor has been highlighted in NCI's Cancer: Changing the Conversation. (Link)

Also See:

  • Taming Difficult to Express Proteins. Angelo DePalma. Genetic Engineering & Biotechnology News. June 15, 2012, 32(12): 1-41. (Link)
  • Altor BioScience Corporation – Company Profile by Hing Wong. Biomarkers Med. (2010) 4(4), 499–504 (ISSN 1752-0363) (10.2217/BMM.10.69 © 2010 Future Medicine Ltd. (Link)
  • NCI SBIR Grants $11 .5M in Bridge Awards. BioWorld Today, December 21, 2009 (Link)
  • Emerging Drug Developer: Altor BioScience. Carroll, John. Fierce Biotech May 4, 2009. (Link)
  • Altor pinpoints treatments to the target. Maurer, Allan. TechJournal South March-April 2009 (Link)
  • Altor BioScience Corp. Kling, Jim Start-Up November 1, 2008 (Link)
  • Altor Bioscience Banks $10M To Propel Pipeline. Gormley, Brian. VentureWire Aug. 27, 2008 (Link)
  • Altor Bioscience Seeks $15M Series C For Cancer Therapy. Gormley, Brian. VentureWire April 25, 2007 (Link)
  • Company Hits Iceberg Solution. South Florida CEO, November 2006 (Link)
  • Altor Moving to Clinic With T-Cell Receptor-Based Drug. Boggs, Jennifer. BioWorld Today, August 10, 2006 (Link)
  • New drug leaves diseased cells nowhere to hide. Coghlan, Andy, New Scientist, April 21, 2002.
  • Miramar firm showcases South Florida's life-science industry. Sun Sentinel, June 3, 2001. (Link)